Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults

European Journal of Neurology

Volumn 23, Issue 5, 2016, Pages 973-978

  Yilmaz, R ^a   Behnke, S ^b   Liepelt Scarfone, I ^a,c   Roeben, B ^a,c   Pausch, C ^b   Runkel, A ^b   Heinzel, S ^a   Niebler, R ^d   Suenkel, U ^a   Eschweiler, G W ^d   Maetzler, W ^a,c   Berg, D ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Parkinson's disease cognition; Substantia nigra hyperechogenicity; Transcranial sonography; Verbal memory

Indexed keywords

ADULT; AGED; APTITUDE TEST; ARTICLE; ATTENTION; BRAIN FUNCTION; COHORT ANALYSIS; ECHOGRAPHY; EXECUTIVE FUNCTION; EXECUTIVE FUNCTION TEST; FEMALE; HUMAN; LANGUAGE; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NORMAL HUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TRANSCRANIAL B MODE SONOGRAPHY; VERBAL MEMORY; VISUO CONSTRUCTIONAL FUNCTION; COGNITION; DIAGNOSTIC IMAGING; MEMORY; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PROCEDURES; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY;

AGED; ATTENTION; COGNITION; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SUBSTANTIA NIGRA; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84960967921     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12974     Document Type: Article

References (24)

1. Liepelt-Scarfone I, Gauss K, Maetzler W, et al. Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. Neuroepidemiology 2013; 41: 174-182.
2. Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013; 28: 216-219.
3. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-1245.
4. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015; 30: 229-237.
5. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015; 14: 57-64.
6. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 2010; 25: 642-646.
7. Thaler A, Mirelman A, Gurevich T, et al. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology 2012; 79: 1027-1032.
8. Liepelt I, Wendt A, Schweitzer KJ, et al. Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population. J Neural Transm 2008; 115: 993-999.
9. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026-1031.
10. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
11. Behnke S, Double KL, Duma S, et al. Substantia nigra echomorphology in the healthy very old: correlation with motor slowing. NeuroImage 2007; 34: 1054-1059.
12. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011; 68: 932-937.
13. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-1165.
14. Sturm W, Willmes K, Horn W. Leistungsprüfsystem für 50-90 jährige (LPS 50+); Handanweisung. 39, 13 S. Göttingen [u.a.]: Hogrefe, 1993.
15. Berg D, Behnke S, Walter U. Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall Med 2006; 27: 12-19.
16. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol 2014; 27: 434-441.
17. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-1126.
18. Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83: 601-606.
19. Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014; 82: 308-316.
20. Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013; 81: 346-352.
21. Sanchez-Ferro A, Benito-Leon J, Louis ED, et al. Rate of cognitive decline in premotor Parkinson's disease: a prospective study (NEDICES). Mov Disord 2013; 28: 161-168.
22. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 2012; 18(Suppl. 1): S199-S202.
23. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-1069.
24. Broeders M, Velseboer DC, de Bie R, et al. Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study. J Int Neuropsychol Soc 2013; 19: 695-708.